Follow us on Twitter
twitter icon@FreshPatents


Autoimmune patents

      

This page is updated frequently with new Autoimmune-related patent applications.

SALE: 440+ Autoimmune-related patent PDFs



 Ddx5 and associated non-coding rnas and modulation of th17 effector function patent thumbnailnew patent Ddx5 and associated non-coding rnas and modulation of th17 effector function
Methods for screening to identify agents capable of modulating ddx5 polypeptide activity are encompassed herein as are methods for using such agents to treat subjects afflicted with th17-mediated inflammatory conditions and autoimmune diseases including, without limitation, crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis, and psoriasis and methods for using such agents to treat subjects afflicted with cancer.. .

 Antibody polypeptides that antagonize cd40 patent thumbnailnew patent Antibody polypeptides that antagonize cd40
Antibody polypeptides that specifically bind a novel epitope of human cd40 are provided. The antibody polypeptides do not exhibit cd40 agonist activity.
Domantis Limited


 Processes and intermediates for making a jak inhibitor patent thumbnailnew patent Processes and intermediates for making a jak inhibitor
This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of janus kinases (jak) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.. .
Incyte Holdings Corporation


 Inhibitors of bruton's tyrosine kinase patent thumbnailnew patent Inhibitors of bruton's tyrosine kinase
Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc


 Screening  the identification of agents capable of activating cd4+cd25+ regulatory t-cells through interactions with the hiv-1 gp120 binding site on cd4 patent thumbnailnew patent Screening the identification of agents capable of activating cd4+cd25+ regulatory t-cells through interactions with the hiv-1 gp120 binding site on cd4
The present invention relates specific activation of a regulatory t cell via a specific cd4 epitope and uses thereof, e.g. For the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction..
Tcf Gmbh


 Enhancement of allogeneic hematopoietic stem cell transplantation patent thumbnailnew patent Enhancement of allogeneic hematopoietic stem cell transplantation
Methods and compositions are provided to augment the conversion of mixed hematopoietic cell chimerism to complete donor cell chimerism following allogeneic hematopoietic cell transplantation (hct), where such transplantation may be utilized for treatment of cancer such as leukemia and lymphoma or for other conditions requiring reconstitution of the hematopoietic system, e.g. Treatment of anemias, thalassemias, autoimmune conditions, and the like.
The Board Of Trustees Of The Leland Stanford Junior University


 Benzazepine dicarboxamide compounds patent thumbnailnew patent Benzazepine dicarboxamide compounds
Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

 Socs mimetics for the treatment of diseases patent thumbnailSocs mimetics for the treatment of diseases
The subject invention concerns peptide mimetics of socs proteins and methods of use. In one embodiment, a peptide mimetic of the invention binds to a socs1 and a socs3 target protein.
University Of Florida Research Foundation, Inc.


 Thiazolopyrrolidine inhibitors of ror-gamma patent thumbnailThiazolopyrrolidine inhibitors of ror-gamma
Provided are novel compounds of formula (i): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ror. Also provided are pharmaceutical compositions comprising the novel compounds of formula (i) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders..
Vitae Pharmaceuticals, Inc.


 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases patent thumbnailApoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Disclosed herein are compounds that inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.. .
Abbvie Inc.


Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors

The present invention provides a heterocyclic compound having a tlr7, tlr9, tlr7/8, tlr7/9 or tlr7/8/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases, inflammatory diseases and the like, in particular, systemic lupus erythematosus, sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof..
Takeda Pharmaceutical Company Limited

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Fumarate compounds, pharmaceutical compositions thereof, and methods of use

Fumarate compounds, pharmaceutical compositions comprising the fumarate compounds, and methods of using fumarate compounds and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, parkinson's disease, huntington's disease, and amyotrophic lateral sclerosis are disclosed.. .

Physiological monitoring for ultrasound therapy

In some examples, a system includes a flexible ultrasound device configured to be attached to an external surface of a patient proximate to an organ of the patient to deliver ultrasound configured to modulate nerve tissue of the patient at the organ. The system further comprises one or more sensors configured to sense one or more physiological parameters indicative of at least one of a symptom treatable by, or a side effect of, the neuromodulation, and processing circuitry configured to control the delivery of ultrasound during an ambulatory period of the patient, and monitor the least one of the symptom or the side effect during the ambulatory period, based on the one or more physiological parameters.
Medtronic, Inc.

Glycotargeting therapeutics

Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired.
École Polytechnique Fédérale De Lausanne (epfl)

Methods and compositions used in treating inflammatory and autoimmune diseases

Methods of treating neuroinflammation by administration of a selective protein c activator, such as recombinant human we thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions for use in the treatment of mammals that exhibit symptoms of neurological inflammation.
The United States Government As Represented By The Department Of Veterans Affairs

Inhibitors of bruton's tyrosine kinase

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Novel heterobicyclic compounds as kappa opioid agonists

The present invention relates to novel compounds of the general formula (i), which are selective and peripherally acting kor agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the kappa (κ) opioid receptors (kor) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, ibd inflammation, ibs inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use..
Cadila Healthcare Limited

Anti-mcam antibodies and associated methods of use

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain. The invention also provides pharmaceutical compositions, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory disease, autoimmune disease, or cancer..
Prothena Biosciences Limited

St2 antigen binding proteins

Described herein are compositions and methods related to antigen binding proteins that bind to human st2, including antibodies. In particular embodiments, the disclosure provides fully human anti-st2 antibodies and deriviatives and variants thereof.
Amgen Inc.

Combination treatment for multiple sclerosis

The present application provides evidence that a combined blockade against alpha-4 integrin and mcam is more effective than against either molecule alone. In consequence, the invention provides methods of combination treatment in which both an antagonist of alpha-4 integrin and an mcam antagonist are administered to a subject having or at risk of multiple sclerosis or other autoimmune disease..
University Of Munster

Targeting agent antibody conjugates and uses thereof

Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells.
The Scripps Research Institute

Compositions and methods for modulating an immune response

Described herein are compositions for increasing il-12 production comprising igg or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing il-12 production comprising an agent that inhibits signaling mediated by interaction between fcrn and igg and uses of said compositions for treating autoimmune diseases.
The Brigham And Women's Hospital, Inc.

A pentacyclic triterpenoid compound with modified structure and preparation method and use thereof

The present invention relates to new pentacyclic triterpenes, their preparation method and use. The compounds of the present invention could effectively treat psoriasis and selectively inhibit in vitro differentiation of the th1 and th17 cells, thereby could be used to treat the th1- or th17-mediated autoimmune diseases..
Suzhou Botany Biomedicals Co., Ltd

Diaryl macrocycles as modulators of protein kinases

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.. .
Tp Therapeutics, Inc.

Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors

Or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein r, r1, r2 and x are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other pim kinase-associated conditions are also disclosed..

Fused amino pyridine as hsp90 inhibitors

The present invention relates to hsp90 inhibitors containing fused amino pyridine core that are useful as inhibitors of hsp90 and their use in the treatment of hsp90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.. .
Curis, Inc.



Autoimmune topics:
  • Autoimmune
  • Immune Disease
  • Autoimmune Disease
  • Immune Diseases
  • Autoimmune Diseases
  • Transplant
  • Immune Disorder
  • Autoimmune Disorder
  • Autoimmune Disorders
  • Infectious
  • Infectious Disease
  • Inflammatory Disease
  • Type 1 Diabetes
  • Proliferative Disorder
  • Recurrence


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.7197

    file did exist - 3095

    0 - 1 - 61